» Articles » PMID: 29738562

Validation of the Quantitative Point-of-care CareStart Biosensor for Assessment of G6PD Activity in Venous Blood

Overview
Journal PLoS One
Date 2018 May 9
PMID 29738562
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the human population affecting an estimated 8% of the world population, especially those living in areas of past and present malaria endemicity. Decreased G6PD enzymatic activity is associated with drug-induced hemolysis and increased risk of severe neonatal hyperbilirubinemia leading to brain damage. The G6PD gene is on the X chromosome therefore mutations cause enzymatic deficiency in hemizygote males and homozygote females while the majority of heterozygous females have an intermediate activity (between 30-80% of normal) with a large distribution into the range of deficiency and normality. Current G6PD qualitative tests are unable to diagnose G6PD intermediate activities which could hinder wide use of 8-aminoquinolines for Plasmodium vivax elimination. The aim of the study was to assess the diagnostic performances of the new Carestart G6PD quantitative biosensor.

Methods: A total of 150 samples of venous blood with G6PD deficient, intermediate and normal phenotypes were collected among healthy volunteers living along the north-western Thailand-Myanmar border. Samples were analyzed by complete blood count, by gold standard spectrophotometric assay using Trinity kits and by the latest model of Carestart G6PD biosensor which analyzes both G6PD and hemoglobin.

Results: Bland-Altman comparison of the CareStart normalized G6PD values to that of the gold standard assay showed a strong bias in values resulting in poor area under-the-curve values for both 30% and 80% thresholds. Performing a receiver operator curve identified threshold values for the CareStart product equivalent to the 30% and 80% gold standard values with good sensitivity and specificity values, 100% and 92% (for 30% G6PD activity) and 92% and 94% (for 80% activity) respectively.

Conclusion: The Carestart G6PD biosensor represents a significant improvement for quantitative diagnosis of G6PD deficiency over previous versions. Further improvements and validation studies are required to assess its utility for informing radical cure decisions in malaria endemic settings.

Citing Articles

CUREMA project: a further step towards malaria elimination among hard-to-reach and mobile populations.

Sanna A, Lambert Y, Jimeno Maroto I, Galindo M, Plessis L, Bardon T Malar J. 2024; 23(1):271.

PMID: 39256842 PMC: 11385508. DOI: 10.1186/s12936-024-05040-8.


Comparative analysis of the quantitative point-of-care CareSTART™ total bilirubin with central laboratory total bilirubin assays in neonatal blood samples.

Chae H, Kwoun W, Lee J, Youn Y Medicine (Baltimore). 2024; 103(21):e38267.

PMID: 38787980 PMC: 11124654. DOI: 10.1097/MD.0000000000038267.


Expanding the roles of community health workers to sustain programmes during malaria elimination: a meeting report on operational research in Southeast Asia.

Dysoley L, Callery J, Bunreth V, Vanna M, Davoeung C, Sovann Y Malar J. 2024; 23(1):2.

PMID: 38166839 PMC: 10759643. DOI: 10.1186/s12936-023-04828-4.


Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review.

Zailani M, Raja Sabudin R, Ithnin A, Alauddin H, Sulaiman S, Ismail E Front Genet. 2023; 14:1098828.

PMID: 37388931 PMC: 10301741. DOI: 10.3389/fgene.2023.1098828.


Village malaria workers for the community-based management of vivax malaria.

Adhikari B, Tripura R, Peto T, Callery J, von Seidlein L, Dysoley L Lancet Reg Health Southeast Asia. 2023; 9:100128.

PMID: 37383038 PMC: 10306055. DOI: 10.1016/j.lansea.2022.100128.


References
1.
Kaplan M, Abramov A . Neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency in Sephardic-Jewish neonates: incidence, severity, and the effect of phototherapy. Pediatrics. 1992; 90(3):401-5. View

2.
Paterakis G, Lykopoulou L, Papassotiriou J, Stamulakatou A, Kattamis C, Loukopoulos D . Flow-cytometric analysis of reticulocytes in normal cord blood. Acta Haematol. 1993; 90(4):182-5. DOI: 10.1159/000204454. View

3.
Thielemans L, Gornsawun G, Hanboonkunupakarn B, Paw M, Porn P, Moo P . Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study. Wellcome Open Res. 2018; 3:1. PMC: 5829521. DOI: 10.12688/wellcomeopenres.13373.1. View

4.
Baird J, Dewi M, Subekti D, Elyazar I, Satyagraha A . Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res. 2014; 165(6):677-88. PMC: 4451869. DOI: 10.1016/j.trsl.2014.09.009. View

5.
Chu C, White N . Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016; 14(10):885-900. PMC: 5039400. DOI: 10.1080/14787210.2016.1220304. View